Antitumor activity of sequential treatment with topotecan and anti- epidermal growth factor receptor monoclonal antibody C225

Clinical Cancer Research

Volumn 5, Issue 4, 1999, Pages 909-916

  Ciardiello, Fortunato ^a   Bianco, Roberto ^a   Damiano, Vincenzo ^a   De Lorenzo, Sonya ^a   Pepe, Stefano ^a   De Placido, Sabino ^a   Fan, Zhen ^b   Mendelsohn, John ^b   Bianco, A Raffaele ^a   Tortora, Giampaolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOPOTECAN; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0032904485     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Sporn, M. B., and Roberts, A. B. Autocrine secretion: ten years later. Ann. Intern. Med., 117: 408-414, 1992.
2. Aaronson, S. A. Growth factors and cancer. Science (Washington DC), 254: 1146-1153, 1991.
3. Salomon, D. S., Brandt, R., Ciardiello, F., and Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 19: 183-232, 1995.
4. Fox, S. B., Smith, K., Hollyer, J., Greenall, M., Hastrich, D., and Harris, A. L. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res. Treat., 29: 41-49, 1994.
5. Fan, Z., and Mendelsohn, J. Therapeutic application of anti-growth factor receptor antibodies. Curr. Opin. Oncol., 10: 67-73, 1998.
6. Baselga, J., and Mendelsohn, J. Type I receptor tyrosine kinases as targets for therapy in breast cancer. J. Mammary Gland Biol. Neopl., 2: 165-174, 1997.
7. Masui, H., Kamrath, H., Apell, G., Houston, L. L., and Mendelsohn, J. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res., 49: 3482-3488, 1989.
8. Arteaga, C. L., Hurd, S. D., Dugger, T. C., Winnier, A. R., and Robertson, J. B. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor α-Pseudomonas exotoxin 40 fusion protein. Cancer Res., 54: 4703-4709, 1994.
9. Kirk, J., Carmichael, J., Stratford, I. J., and Harris, A. L. Selective toxicity of TGF-α-PE40 to EGFR-positive cell lines: selective protection of low EGFR-expressing cell lines by EGF. Br. J. Cancer, 69: 988-994, 1994.
10. Lorimer, I. A. J., Wikstrand, C. J., Batra, S. K., Bigner, D. D., and Pastan, I. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin. Cancer Res., 1: 859-864, 1995.
11. Schmidt, M., and Wels, W. Targeted inhibition of tumor cell growth by a bispecific single-chain toxin containing an antibody domain and TGFα. Br. J. Cancer, 74: 853-862, 1996.
12. Buchdunger, E., Mett, H., Trinks, U., Regenass, U., Muller, M., Meyer, T., Beilstein, P., Wirz, B., Schneider, P., Traxler, P., and Lydon, N. 4,5-Bis(4-fluoroanilino)phthalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity. Clin. Cancer Res., 1: 813-821, 1995.
13. Gill, G. N., Kawamoto, T., Cochet, C., Lee, A., Sato, J. D., Masui, H., MacLeod, C., and Mendelsohn, J. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem., 259: 7755-7760, 1984.
14. Masui, H., Kawamoto, T., Sato, J. D., Wolf, B., Sato, G., and Mendelsohn, J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res., 44: 1002-1007, 1984.
15. Aboud-Pirak, E., Hurwitz, E., Pirak, M. E., Bellot, F., Schlessinger, J., and Sela, M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J. Natl. Cancer Inst., 80: 1605-1611, 1988.
16. Modjtahedi, H., Eccles, S., Box, G., Styles, J., and Dean, C. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br. J. Cancer, 67: 254-261, 1993.
17. Goldstein, N. I., Prewett, M., Zuklys K., Rockwell, P., and Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1: 1311-1318, 1995.
18. Falcey, J., Pfister, D., Cohen, R., Cooper, M., Bowden, C., Burtness, B., Mendelsohn, J., and Waksal, H. A study of anti-epidermal growth factor receptor (EGFr) monoclonal antibody C225 and cisplatin in patients (pts) with head and neck or lung carcinomas. Proc. Am. Soc. Clin. Oncol., 16: 1364, 1997.
19. Fan, Z., Baselga, J., Masui, H., and Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res., 53: 4637-4642, 1992.
20. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., and Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst., 85: 1327-1333, 1993.
21. Carmichael, J., and Ozols, R. F. Topotecan, an active new antineoplastic agent: review and current status. Exp. Opin. Invest. Drugs, 6: 593-608, 1997.
22. Giannakakou, P., Sackett, D. L., Kang, Y-K., Zhan, Z., Buters, J. T. M., Fojo, T., and Poruchynsky, M. S. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem., 272: 17118-17125, 1997.
23. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
24. Ciardiello, F., Darniano, V., Bianco, C., di Isernia, G., Ruggiero, A., Caraglia, M., Tagliaferri, P., Baselga, J., Mendelsohn, J., Bianco, A. R., and Tortora, G. Cooperative antiproliferative effects of 8-C1-cAMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells. Clin. Cancer Res., 1: 161-167, 1995.
25. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., and Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139: 271-279, 1991.
26. Ciardiello, F., Damiano, V., Bianco, R., Bianco, C., Fontanini, G., De Laurentiis, M., De Placido, S., Mendelsohn, J., Bianco, A. R., and Tortora, G. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J. Natl. Cancer Inst., 88: 1770-1776, 1996.
27. Fleiss, J. L. Statistical Methods for Rates and Proportions, Ed. 2. New York: Wiley, 1981.
28. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem. Rep., 50: 163-170, 1966.
29. Wosikowski, K., Schuurhuis, D., Johnson, K., Paull, K. D., Myers, T. G., Weinstein, J. N., and Bates, S. E. Identification of epidennal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J. Natl. Cancer Inst., 89: 1505-1515, 1997.
30. Mendelsohn, J., and Fan, Z. Epidermal growth factor receptor family and chemosensitization. J. Natl. Cancer Inst., 89: 341-343, 1997.
31. Vickers, P. J., Dickson, R. B., Shoemaker, R., and Cowan, K. H. A multidrug resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol. Endocrinol., 2: 886-892, 1988.
32. Meyers, M. B., Shen, W. P. V., Spengler, B. A., Ciccarone, V., O'Brien, J. P., Donner, D. B., Furth, M. E., and Biedler, J. L. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J. Cell. Biochem., 38: 87-97, 1988.
33. Wosikowski, K., Schuurhuis, D., Kops, G. J. P. L., Saceda, M., and Bates, S. E. Altered gene expression in drug-resistant human breast cancer cells. Clin. Cancer Res., 2: 2405-2414, 1997.
34. 1 arrest in prostatic cancer cell line DU145. Cancer Res., 56: 3666-3669, 1996.
35. KIP1 in G1 arrest mediated by anti-epidermal growth factor receptor monoclonal antibody. Oncogene, 12: 1397-1403, 1996.
36. Hancock, M. C., Langton, B. C., Chan, T., Toy, P., Monhanan, J. J., Mischak, R. P., and Shawer, L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloro-platinum against human breast and ovarian tumor cell lines. Cancer Res., 51: 4574-4580, 1991.
37. Arteaga, C. L., Winnier, A. R., Poirer, M. C., Lopez-Larraza, D. M., Shawer, L. K., Hurd, S. D., and Stewart, S. J. p185c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res., 54: 3758-2765, 1994.
38. Pietras, R. J., Fendly, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B., and Slamon, D. J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene, 9: 1829-1838, 1994.
39. Baselga, J., Norton, L., Albanell, J., Kim, Y-M., and Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res., 58: 2825-2831, 1998.
40. Pietras. R. J., Pegram. M. D., Finn, R. S., Maneval, D. A., and Slamon, D. J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene. 17: 2235-2249, 1998.
41. Tortora, G., di Isernia, G., Sandomenico, C., Bianco, R., Pomatico, G., Pepe, S., Bianco, A. R., and Ciardiello, F. Synergistic inhibition of growth and induction of apoptosis by 8-Chloro-cAMP and paclitaxel or cisplatin in human cancer cells. Cancer Res., 57: 5107-5111, 1997.
42. Tortora, G., Caputo, R., Damiano, V., Bianco, R., Pepe, S., Bianco, A. R., Jiang, Z., Agrawal, S., and Ciardiello, F. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc. Natl. Acad. Sci. USA, 94: 12586-12591, 1997.
43. Ciardiello, F., and Tortora, G. Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. Clin. Cancer Res., 4: 821-828, 1998.
44. Geiger, T., Muller, M., Monia, B. P., and Fabbro, D. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Clin. Cancer Res., 3: 1179-1185, 1997.
45. Anderson, V., Cooper, M., O'Chei, E., Gilly, J., Falcey, J., and Waksal, H. W. Dose dependent pharmacokinetics of a chimerized monoclonal antibody (C225) against EGFR. Proc. Am. Assoc. Cancer. Res., 39: 3561, 1998.
46. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 16: 2659-2671, 1998.
47. Slamon, D. J., Leyland-Jones, B., Shak, S., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Volter, J., Baselga, J., and Norton, L. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized multinational controlled phase III trial. Proc. Am. Soc. Clin. Oncol., 17: 377, 1998.